Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Mutation Discovered in Familial Chronic Diarrhea Syndrome

By LabMedica International staff writers
Posted on 01 Apr 2012
One heritable DNA mutation has been discovered that leads to chronic diarrhea and bowel inflammation, which contributes the pathology of the diseases. More...


A protein made from a specific gene is involved in transmitting specific chemical signals from food consumed to the cells inside the bowels, but family members with chronic diarrhea have a mutation that makes the protein transmit more signal than it should.

Investigators at HudsonAlpha Institute for Biotechnology (Huntsville, AL, USA) working with scientists from Norway and India, studied a Norwegian family with a number of related inflammatory bowel conditions. There were 32 affected persons from three branches of the same family as well as 14 unaffected family members. Such a large family allowed scientists in Norway to use traditional methods to narrow down the potential DNA mutation to one portion of chromosome 12, and then to a specific gene called guanylate cyclase 2C (GUCY2C). They used linkage analysis, based on arrays with single-nucleotide polymorphisms (SNPs), to identify a candidate region.

Genomic DNA was purified from blood with the use of the QIAsymphony system (Qiagen, Germantown, MD, USA). Whole-genome genotyping of SNPs was performed with the use of GeneChip Human Mapping Array (Affymetrix, Santa Clara, CA, USA). Linkage analysis of samples from 11 affected members and 14 healthy members of one family branch revealed only one significant shared region in the affected members, on the short arm of chromosome 12. The scientists are now evaluating possible drug treatments based on the function of the affected protein. They can also recommend that GUCY2C be reexamined in more common bowel inflammation syndromes, as it may contribute to pathology for thousands of people worldwide.

Shawn E. Levy, PhD, a faculty investigator at HudsonAlpha said, "Based on the effects seen from this one mutation, we are hopeful that the work will aid in understanding of much more common diseases like Crohn's and irritable bowel syndrome, which also have inflammation and diarrhea as symptoms." The study was published on March 21, 2012, in the New England Journal of Medicine (NEJM).

Related Links:
HudsonAlpha Institute
Qiagen
Affymetrix



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.